PMID- 17255279
OWN - NLM
STAT- MEDLINE
DCOM- 20070424
LR  - 20210102
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 13
IP  - 2 Pt 1
DP  - 2007 Jan 15
TI  - Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic 
      cell-based therapeutics.
PG  - 566-575
LID - 10.1158/1078-0432.CCR-06-1576 [doi]
AB  - PURPOSE: Allogeneic glioma cell lines that are partially matched to the patient 
      at class I human leukocyte antigen (HLA) loci and that display tumor-associated 
      antigens (TAA) or antigenic precursors [tumor antigen precursor proteins (TAPP)] 
      could be used for generating whole tumor cell vaccines or, alternatively, for 
      extraction of TAA peptides to make autologous dendritic cell vaccines. 
      EXPERIMENTAL DESIGN: Twenty human glioma cell lines were characterized by 
      molecular phenotyping and by flow cytometry for HLA class I antigen expression. 
      Twelve of the 20 cell lines, as well as analyses of freshly resected glioma 
      tissues, were further characterized for protein and/or mRNA expression of 16 
      tumor antigen precursor proteins or TAA. RESULTS: These 20 human glioma cell 
      lines potentially cover 77%, 85%, and 78% of the U.S. Caucasian population at 
      HLA-A, HLA-B, and HLA-C alleles, respectively. All cells exhibited multiple TAA 
      expressions. Most glioma cells expressed antigen isolated from immunoselected 
      melanoma-2 (Aim-2), B-cyclin, EphA2, GP100, 
      beta1,6-N-acetylglucosaminyltransferase V (GnT-V), IL13Ralpha2, Her2/neu, hTert, 
      Mage, Mart-1, Sart-1, and survivin. Real-time PCR technology showed that 
      glioblastoma specimens expressed most of the TAA as well. Tumor-infiltrating 
      lymphocytes and CD8(+) CTL killed T2 cells when loaded with specific HLA-A2(+) 
      restricted TAA, or gliomas that were both HLA-A2(+) and also positive for 
      specific TAA (Mart-1, GP100, Her2/neu, and tyrosinase) but not those cells 
      negative for HLA-A2 and/or lacking the specific epitope. CONCLUSIONS: These data 
      provide proof-in-principle for the use of allogeneic, partially HLA 
      patient-matched glioma cells for vaccine generation or for peptide pulsing with 
      allogeneic glioma cell extracts of autologous patient dendritic cells to induce 
      endogenous CTL in brain tumor patients.
FAU - Zhang, Jian Gang
AU  - Zhang JG
AD  - Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long 
      Beach, California.
AD  - Pathology Department, Neurooncology Program, Chao Cancer Center, University of 
      California, Irvine, Irvine, California.
FAU - Eguchi, Junichi
AU  - Eguchi J
AD  - Neurological Surgery, University of Pittsburgh School of Medicine, Brain Tumor 
      Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, 
      Pittsburgh, Pennsylvania.
FAU - Kruse, Carol A
AU  - Kruse CA
AD  - La Jolla Institute for Molecular Medicine, San Diego, California.
FAU - Gomez, German G
AU  - Gomez GG
AD  - La Jolla Institute for Molecular Medicine, San Diego, California.
FAU - Fakhrai, Habib
AU  - Fakhrai H
AD  - NovaRx Corporation, San Diego, California.
FAU - Schroter, Stephanie
AU  - Schroter S
AD  - University of California, San Diego Cancer Center, La Jolla, California.
FAU - Ma, Wenxue
AU  - Ma W
AD  - University of California, San Diego Cancer Center, La Jolla, California.
FAU - Hoa, Neil
AU  - Hoa N
AD  - Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long 
      Beach, California.
AD  - Pathology Department, Neurooncology Program, Chao Cancer Center, University of 
      California, Irvine, Irvine, California.
FAU - Minev, Boris
AU  - Minev B
AD  - University of California, San Diego Cancer Center, La Jolla, California.
FAU - Delgado, Christina
AU  - Delgado C
AD  - Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long 
      Beach, California.
AD  - Pathology Department, Neurooncology Program, Chao Cancer Center, University of 
      California, Irvine, Irvine, California.
FAU - Wepsic, H Terry
AU  - Wepsic HT
AD  - Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long 
      Beach, California.
AD  - Pathology Department, Neurooncology Program, Chao Cancer Center, University of 
      California, Irvine, Irvine, California.
FAU - Okada, Hideho
AU  - Okada H
AD  - Neurological Surgery, University of Pittsburgh School of Medicine, Brain Tumor 
      Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, 
      Pittsburgh, Pennsylvania.
FAU - Jadus, Martin R
AU  - Jadus MR
AD  - Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long 
      Beach, California.
AD  - Pathology Department, Neurooncology Program, Chao Cancer Center, University of 
      California, Irvine, Irvine, California.
LA  - eng
GR  - P01 NS 40923/NS/NINDS NIH HHS/United States
GR  - F31 CA 94834/CA/NCI NIH HHS/United States
GR  - R44 CA 105964/CA/NCI NIH HHS/United States
GR  - F31 CA094834/CA/NCI NIH HHS/United States
GR  - NS 046463/NS/NINDS NIH HHS/United States
GR  - R44 CA105964/CA/NCI NIH HHS/United States
GR  - P01 NS040923/NS/NINDS NIH HHS/United States
GR  - NS 056300/NS/NINDS NIH HHS/United States
GR  - R21 NS056300/NS/NINDS NIH HHS/United States
GR  - R21 NS046463/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Antigens/*biosynthesis
MH  - Antineoplastic Agents/*pharmacology
MH  - Brain Neoplasms/*immunology/therapy
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*cytology
MH  - Flow Cytometry
MH  - Genes, MHC Class I
MH  - Glioma/*immunology/*therapy
MH  - HLA Antigens/biosynthesis
MH  - Humans
MH  - Immunotherapy/instrumentation/*methods
MH  - Microscopy, Fluorescence
MH  - Phenotype
MH  - Transplantation, Homologous
PMC - PMC4030524
MID - NIHMS573441
EDAT- 2007/01/27 09:00
MHDA- 2007/04/25 09:00
PMCR- 2014/05/22
CRDT- 2007/01/27 09:00
PHST- 2007/01/27 09:00 [pubmed]
PHST- 2007/04/25 09:00 [medline]
PHST- 2007/01/27 09:00 [entrez]
PHST- 2014/05/22 00:00 [pmc-release]
AID - 10.1158/1078-0432.CCR-06-1576 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575. doi: 
      10.1158/1078-0432.CCR-06-1576.